EX
Exelixis
EXEL · NASDAQ
$59.01 +0.87% (+$0.51)
1M +9.14%
Market Cap $14.9B
P/E Ratio 17.27x
Div. Yield -
ROE 42.49%
Bulios Fair Price
$66.42
12.6% upside
Current Price
$59.01
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EXEL is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
63 /100
Fair EV/EBITDA 14.18x
P/S 6.10x
P/B 8.06x
Growth
83 /100
Growing Rev. growth 12.93%
FCF growth 55.59%
Book val. growth 4.59%
Profitability
100 /100
Strong Net margin 35.33%
Op. margin 39.88%
FCF margin 48.47%
Quality
97 /100
Excellent ROE 42.49%
ROA 34.50%
Asset turnover 0.98x
Debt
100 /100
Low Current ratio 3.46x
Net debt/EBITDA -0.11x
Debt/Equity 0.09x
Stability
59 /100
Moderate Rev. volatility 5.78%
EPS volatility 80.01%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EXEL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Morrissey
Employees
1,077
Headquarters
Alameda
Upcoming events
03 NOV
Earnings
Upcoming earnings report